Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort

Clin Infect Dis. 2022 Sep 10;75(4):715-718. doi: 10.1093/cid/ciac086.


Among 14 049 people with human immunodeficiency virus in care in 2019-2020, 96% were treated with antiretroviral therapy (ART). Current antiretroviral treatment patterns highlight high uptake of guideline-recommended ART regimens including second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) and tenofovir alafenamide, especially in antiretroviral-naive individuals initiating ART.

Keywords: ART guidelines; ART treatment trends; ART utilization; integrase inhibitor; tenofovir alafenamide.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Acquired Immunodeficiency Syndrome* / drug therapy
  • Alanine / therapeutic use
  • Anti-HIV Agents* / therapeutic use
  • Anti-Retroviral Agents / therapeutic use
  • Emtricitabine / therapeutic use
  • HIV
  • HIV Infections* / drug therapy
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Tenofovir / therapeutic use
  • United States


  • Anti-HIV Agents
  • Anti-Retroviral Agents
  • Heterocyclic Compounds, 3-Ring
  • Tenofovir
  • Emtricitabine
  • Alanine